Dr. Gabriela Borșaru

Education

• 1983 - 1989: University of Medicine and Pharmacy "Carol Davila", Bucharest
• 1991 - 1994: Residency - Internal Medicine
• 1994 - 1999: Resident Hematology
• 1999: Senior Internal Medicine
• Since 2003: Senior Hematologist
• 1999 - 2006: Doctorate

Experience

• Coltea Clinical Hospital, primary care physician Internal Medicine, Clinical Hematology, Doctor of Medical Sciences since 2006
• Primary Care Internal Medicine
• First Clinical Hematology Physician
• Molecular Biology, 1999 - 2008: Victor Babes Institute Molecular Biology Laboratory and Coltea Hospital Clinical Molecular Biology Laboratory
• Doctor of Medical Sciences 2006 with the paper "Molecular expression of the Philadelphia chromosome in chronic lymphocytic leukemia and acute lymphoblastic leukemia PH +"
• Molecular Biology Overspecialization - Scholarship Oct 1997 - Sep 1998 Institute Seragnoli Bologna Italy
• Stem cell processing March-June 2012 Institute Seragnoli Bologna

Clinical experience

• 2008 - 2009: Refractory / Relapsed Ofatumumab DBCLL2
• 2010 - 2012: Refractory / Relapsed Resmonistat Hodgkin's Lymphoma
• 2007 - 2008: CEP (FLT3 inhibitor in acute myeloblastic leukemia FLT3 +
• 2005 - 2006: Anemia in lymphoproliferative diseases
• 2005 - 2006: Anemia in neoplastic diseases
• 2004 - 2005: Growth factor after chemotherapy -in lymphoma
• 2010 - 2011: Chronic idiopathic thrombocytopenic purpura - immunoglobulin for IPT with <20,000 PLT / DL 5
• 2011 - 2012: Ironic iron thrombocytopenic purpura - immunoglobulin for IPT with <30,000 PLT / DL
• 2011 - 2013: The first line multiple myeloma with Elotuzumab
• 2011 - 2013: Multiple refractory / relapsed myeloma with Elotuzumab
• 2012 - 2014: Multiple refractory / relapsed myeloma with Proteasoma - oral inhibitor
• 2011 - 2013: Anti JAK 2 in metaplasia myeloid akarta
• 2013 - 2015: Anti-CD in the first line of follicular lymphoma
• 2014 - 2015: Anti-CD in the first line of low-load follicular lymphoma
• 2012 - 2013: Blinatumubab acute lymphoblastic leukemia
• 2010 - 2011: Chronic myeloid leukemia-Bosutinib
• 2013: Febuxostat in TLS
• 2014 - present: Daratumubab for first-line multiple myeloma
• 2017 - 2020: Anti-FLT 3 in Leukemia Alm FLT3 +
• 2018 - 2020: Anti FLT 3 in AML in remission
• 2018 - 2020: Parcinostat in AML for the elderly
• 2016 - 2018: Immunoglobulin in ITP
• 2018 - 2019: Inhibitors bruton liase in MCL
• 2018 - present: Pik 3 Rituximab in NHL indolent lymphoma
• 2016 - 2017: Anti CD 20 in follicular lymphoma with reduced pregnancy
• 2017 - 2018: 2017 Anti CD 20 in follicular lymphoma with reduced pregnancy
• 2018 - 2021: PIK 3 RITUXIMAB + BENDAMUSTIN in lifeless indolent R / R
• 2021 - present: TKI in CML registent to Pomalidomide
• 2021 - present: Momelotinib in MMAC resistant to JAKAFI
• 2021 - present: Monoclonal antibody in chronic ITP
• 2020 - present: Anti cd-20 IN FL low load first line
• 2021 - present: Hemolytic Anemia
• 2009- Biphosphonates in multiple myeloma
• 2010 - 2011: Anti-hermetic in NHL chemotherapy
• 2014 - 2018: Temsirolimus in refractory / relapsed Mantel cell lymphoma

Licences

• Member of professional associations: Romanian Society of Hematology
• 1997 - 1998: Molecular Biology - in Chronic - "Seragnoli Institute" Bologna, Italy
• 2002 - 2004: REAL TIME PCR - “Seragnoli Institute ” Bologna, Italy
• 2004: Stem cells

Publications

• A multicenter, phase II ofatumumab monotherapy process in relapsed / progressive large B-cell lymphoma. Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S; 415 investigators of the study. Br J Haematol. 2013 November; 163 (3): 334-42. doi: 10.1111 / bjh.12537. EPub 2013 Aug 23. Erratum in: Br J Haematol. 2014 Maybe; 165 (3): 422. Verhoef, Gregor [added].
• Daratumumab plus Bortezomib, Melphalan and Prednisone for untreated myeloma. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T , Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; Alcyone. N Engl J Med. 2018 Feb 8; 378 (6): 518-528. doi: 10.1056 / NEJMoa1714678. EPub 2017 December
• Impact of previous therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed / refractory multiple myeloma in TOURMALINE-MM1. Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H , Richardson PG, Moreau P. Haematologica. 2017 Oct; 102 (10): 1767-1775. doi: 10.3324 / haematol.2017.170118. Epub 2017 Jul 27
• Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S , Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 study group. N Engl J Med. 2016 Apr 28; 374 (17): 1621-34. doi: 10.1056 / NEJMoa1516282.
• FLORENCE: A randomized, double-blind, pivotal phase III study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with haematological malignancies from intermediate to high-risk tls. Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S , Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. Ann Oncol. 2015 Oct; 26 (10): 2155-61. doi: 10.1093 / annonc / mdv317. EPub 2015 Jul 27.
• Phase IV multicenter study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin's lymphoma undergoing repeated cycles of moderate emetogenic chemotherapy. Choi BS, Borsaru GP, Ballinari G, Voisin D, Di Renzo N. Lymphoma leuk. 2014 Mar; 55 (3): 544-50. doi: 10.3109 / 10428194.2013.813498. EPub 2013 Jul 24.
• Association of 3q21q26 syndrome with various RPN1 / EVI1 fusion transcripts. Martinelli G, Ottaviani E, Buonamici S, Isidori A, Borsaru G, Visani G, Piccaluga PP, Malagola M, Testoni N, Rondoni M, Nucifora G, Tura S, Baccarani M. Hematologica. 2003 November; 88 (11): 1221-8.
• Cytogenetic abnormalities 3q21 and 3q26 in acute myeloblastic leukemia: biological and clinical features. Testoni N, Borsaru G, Martinelli G, Carboni C, Ruggeri D, Ottaviani E, Pelliconi S, Ricci P, Pastano R, Visani G, Zaccaria A, Tura S. Hematologica. 1999 Aug; 84 (8): 690-4.

---

Hematology

Investigation	Price
	230 lei
	350 lei
	350 lei
	250 lei